GO
Loading...

Mylan Inc

More

  • July 16- Abbott Laboratories Inc reported better-than-expected quarterly earnings on Wednesday as demand for its recently-recalled infant formulas began to recover and profit margins improved for other business segments.

  • Abbott 2Q profit falls on higher taxes, revenue up Wednesday, 16 Jul 2014 | 9:22 AM ET

    The generic drugmaker Mylan Inc. announced this week that it is buying Abbott's generic-drugs business in developed markets for stock valued at about $5.3 billion. For the period ended June 30, Abbott— which makes infant formula like Similac as well as medical devices and drugs— earned $466 million, or 30 cents per share.

  • How US drug firms plan to evade taxes Tuesday, 15 Jul 2014 | 5:35 AM ET

    Increasingly, drug makers and medical device companies have found a way to self-medicate when it comes to taxes and regulation.

  • Citigroup and Mylan are big market movers Monday, 14 Jul 2014 | 4:57 PM ET

    NEW YORK— Stocks that moved substantially or traded heavily Monday on the New York Stock Exchange and the Nasdaq Stock Market:. Kodiak Oil& Gas Corp., up 68 cents to $14.91. URS Corp., up $6.38 to $58.40.

  • *Citigroup to pay $7 bln to settle U.S. mortgage probe. NEW YORK, July 14- U.S. stocks ended higher on Monday, with the Dow Jones industrial average hitting an intraday record, lifted by Citigroup's better-than-expected earnings and more deals in the healthcare space. Citigroup Inc shares jumped 3 percent to $48.42 and gave the S&P 500 one of its biggest boosts.

  • Stocks end higher on M&A; Dow sets intraday record Monday, 14 Jul 2014 | 4:50 PM ET
    Trader on the floor of the New York Stock Exchange.

    Stocks climbed on Monday, with the S&P 500 bouncing back from weekly losses, after Citigroup's earnings beat estimates.

  • US companies look overseas for tax bill relief Monday, 14 Jul 2014 | 3:05 PM ET

    Generic drugmaker Mylan Inc. said Monday it will become part of a new company organized in the Netherlands in a $5.3 billion deal to acquire some of Abbott Laboratories' generic-drugs business.

  • *Citigroup to pay $7 bln to settle U.S. mortgage probe. NEW YORK, July 14- U.S. stocks rose on Monday with the Dow Jones industrial average hitting a new intraday high, lifted by better than expected earnings from Citigroup and more deals in the healthcare space.

  • July 14- Generic drugmaker Mylan Inc said on Monday it would buy Abbott Laboratories' branded specialty and generics business in developed markets outside the United States in a $5.3 billion deal that will bolster its product line and also cut its tax bill.

  • *Citigroup up after earnings, settlement. NEW YORK, July 14- U.S. stocks rose on Monday, sparked by the latest flurry of merger activity and earnings from Citigroup, putting the S&P 500 on pace to climb for a second straight session.

  • Big shale deal may be easy money or strong market Monday, 14 Jul 2014 | 10:03 AM ET
    Traders on the floor of the New York Stock Exchange.

    Big mergers are afoot. But is a major shale oil deal a sign of a strong market?

  • FACTBOX-M&A frenzy transforming global pharma Monday, 14 Jul 2014 | 9:27 AM ET

    July 14- Several multi-billion dollar deals and bids have made 2014 a busy year for healthcare acquisitions, despite Pfizer pulling its $118 billion offer for AstraZeneca.

  • NEW YORK, July 14- U.S. stocks were poised for a higher open on Monday after the latest flurry of merger activity and earnings from Citigroup, putting the S&P 500 on track to rebound from its worst weekly decline since April.

  • Mylan in $5.3B deal for Abbott's generics assets Monday, 14 Jul 2014 | 8:47 AM ET

    Mylan said it would buy Abbott Labs' generics business outside the United States in an all-stock transaction valued at about $5.3 billion.

  • Early movers: C, AAPL, MYL, BID, EBAY, GE & more Monday, 14 Jul 2014 | 8:06 AM ET
    Traders on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • US STOCKS-Futures higher on M&A after down week Monday, 14 Jul 2014 | 7:40 AM ET

    *Shire accepts Abbvie takeover offer. *London- listed drugmaker Shire Plc succumbed to an increased 31 billion pounds takeover offer from Abbvie Inc, ending a long-running courtship largely motivated by tax rates. U.S.-listed shares of Shire rose 2.4 percent to $255.10 while Abbvie shed 0.7 percent to $54.56 in premarket trade.

  • July 14- Generic drugmaker Mylan Inc said it would buy Abbott Laboratories' specialty and branded generics business in developed markets outside the United States in an all-stock transaction valued at about $5.3 billion.

  • Mylan to buy Abbott business line in $5.3B deal Monday, 14 Jul 2014 | 6:59 AM ET

    PITTSBURGH— The generic drugmaker Mylan is buying Abbott Laboratories' generic-drugs business in developed markets for stock valued at about $5.3 billion. The business to be acquired by Mylan encompasses more than 100 generic and specialty drugs sold in Europe, Japan, Canada, Australia and New Zealand. It also include manufacturing plants in France and Japan.

  • July 14- Generic drugmaker Mylan Inc said it would buy Abbott Laboratories' specialty and branded generics business outside the United States in an all-stock transaction valued at about $5.3 billion.

  • *AbbVie raises bid to 53.20/ share from 51.15. *Bid comprises 24.44 stg cash and 0.8960 new AbbVie shares. LONDON, July 14- London- listed drugmaker Shire Plc succumbed to an increased 31 billion pounds takeover offer from Abbvie Inc on Monday, signaling the conclusion to a long-running courtship largely motivated by tax.